Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
15°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaccitech Plc ADR
(NQ:
VACC
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaccitech Plc ADR
< Previous
1
2
3
4
Next >
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
November 06, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 31, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 09, 2023
It's time to start off the week with a breakdown of the biggest pre-market stock movers that investors need to know about for Monday!
Via
InvestorPlace
Analyst Expectations for Vaccitech's Future
June 13, 2023
Via
Benzinga
Vaccitech: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
Vaccitech Earnings Perspective: Return On Capital Employed
March 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
September 25, 2023
Via
Benzinga
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
September 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
September 13, 2023
From
Vaccitech plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Monday's session saw 175 companies set new 52-week lows.
Via
Benzinga
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 10, 2023
From
Vaccitech plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
On Thursday, 283 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 04, 2023
Via
Benzinga
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
June 21, 2023
From
Vaccitech plc
Via
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
June 12, 2023
From
Vaccitech plc
Via
GlobeNewswire
Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
June 02, 2023
The Dow Jones closed higher by around 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
April 17, 2023
From
Vaccitech plc
Via
GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
April 05, 2023
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.
Via
InvestorPlace
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
March 28, 2023
From
Vaccitech plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
March 24, 2023
Via
Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 24, 2023
Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50.
Via
Benzinga
Crude Oil Down 1%; US Composite PMI Jumps In March
March 24, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 80 points on Friday. The Dow traded down 0.26% to 32,021.81 while the NASDAQ fell 0.41% to 11,739.58. The S&P 500,...
Via
Benzinga
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
March 24, 2023
From
Vaccitech plc
Via
GlobeNewswire
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
March 20, 2023
From
Vaccitech plc
Via
GlobeNewswire
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 23, 2023
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
Via
Benzinga
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
January 30, 2023
From
Vaccitech plc
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.